Background Assessment of the kinetics of SARS-CoV-2 antibodies is essential in predicting
risk of reinfection and durability of vaccine protection. Methods This is a prospective, …

Importance Risk factors associated with the severity of coronavirus disease 2019 (COVID-19)
in patients with multiple sclerosis (MS) are unknown. Disease-modifying therapies (DMTs) …

Objective To describe clinical and radiologic features associated with myelin oligodendrocyte
glycoprotein antibodies (MOG-Ab) in a large French nationwide adult cohort, to assess …

Background and purpose Neurological manifestations in coronavirus disease (COVID)‐2019
may adversely affect clinical outcomes. Severe COVID‐19 and uremia are risk factors for …

Background: There have been few epidemiologic studies on neuromyelitis optica (NMO)
and none used the recent 2006 diagnostic criteria. Here we describe the clinical, laboratory, …

Objective The main objective was to compare clinical features, disease course, and myelin
oligodendrocyte glycoprotein (MOG) antibody (Ab) dynamics between children and adults …

Background The serologic response of individuals with mild forms of SARS-CoV-2 infection
is poorly characterized. Methods Hospital staff who had recovered from mild forms of PCR-…

Objective: To optimize aquaporin-4 (AQP4) antibody (Ab) detection and to assess the
influence of the increased sensitivity of the assay on the demographic and disease-related …

Background Antibodies against myelin oligodendrocyte glycoprotein (MOG) have been
identified in a subgroup of pediatric patients with inflammatory demyelinating disease of the …

Background and Objectives To evaluate the long-term safety and efficacy of tocilizumab (TCZ),
a humanized anti–interleukin-6 receptor antibody in myelin oligodendrocyte glycoprotein–…